COVID-19: information on veterinary medicines
The European Medicines Agency (EMA) and its partners in the European medicines regulatory network are closely monitoring the potential impact of the COVID-19 pandemic on the veterinary medicine supply chain in the European Union (EU). They are also providing guidance for marketing authorisation holders of veterinary medicines on adaptations to the regulatory framework to address some of the constraints posed by the pandemic.
Regulatory information on the impact of the COVID-19 pandemic on veterinary medicines is contained together with the information on human medicines. Please refer to the relevant content in the human regulatory section:
- Availability of medicines during COVID-19 pandemic
- Guidance for medicine developers and other stakeholders on COVID-19
Veterinary stakeholders can also follow all the latest updates from EMA on COVID-19, including news and press releases: